Objective: To evaluate the cost-effectiveness of bendamustine-rituximab (B-R) compared with CHOP-R and CVP-R as first-line treatment for patients with advanced indolent non-Hodgkin’s lymphoma (NHL).
Objective: To evaluate the cost-effectiveness of bendamustine-rituximab (B-R) compared with CHOP-R and CVP-R as first-line treatment for patients with advanced indolent non-Hodgkin’s lymphoma (NHL).